

>>> Helping you deliver medical breakthroughs. Because patients can't wait.

At Parexel Biotech, we focus on meeting your patients' needs. The most critical and innovative new therapies, and those for rare and untreated diseases, are in the biotech pipeline. We have tailored biotech-specific solutions that connect essential services supported by dedicated experienced leadership and resources. Patients are waiting for more effective and better-tolerated therapies and our mission is to help you deliver them. From development strategy, meeting clinical development timelines, optimizing product and pipeline value, to navigating competitive, regulatory and reimbursement landscapes, we connect essential capabilities with a passionate, can-do culture to bring success for you



Your challenges

- Navigating complex
- competitive, regulatory and reimbursement landscapes
- Managing complex funding environment and limited resources
- Defining the right

 development

 and post-launch path
- Orchestrating increasing trial complexity and associated site burden
- Applying the latest drug development **innovations** to improve the likelihood of launch
- The need to demonstrate proof-of-concept
- Identifying the optimal protocol design
- Selecting the **right sites**for **optimized**patient **recruitment**



>>> A strong plan helps you hit your targets

Smart, early planning is essential. Considering the needs of your key stakeholders, investors, regulators, payers, physicians and patients can optimize your development program to save time and resources. We'll help you map out your development journey to identify potential risks and how to avoid them.



We'll help you reach your goals faster. How we do it:



Assign a dedicated point of contact to meet project timelines



Invest dedicated resources in emerging and mid-size sponsors



Deliver executive sponsorship to support ongoing success



Provide access to specialized resources from world-class experts, including former regulators



Develop an integrated, customized strategy to minimize complexity, accelerate timeliness and reduce fixed costs



Leverage adaptive, synthetic and/or flexible trial designs for maximum efficiency



Apply industry-leading translational medicine expertise¹



Implement innovative patient-centric solutions² and the latest thinking around real-world data and evidence

2. e.g., hybrid or virtual trials

^{1.} Including quantitative clinical development, biomarkers and genomics (enabling delivery of precision medicine), and bioanalysis



>>> We offer guidance and experience with flexibility

You're driven by the goal to make life better for your patients. We're here to help make sure that happens.

- >>> Here's what we can do:
 - Give you strategic guidance
 - Innovate and streamline your development program
 - Extend your reach
 - Integrate your approach
 - Navigate therapeutic areas
 - Mitigate your risks

>>> Biotech is a fast-growing, competitive environment

The R&D pipeline keeps on growing, year on year...3

170%

increase in number of drugs in R&D pipeline between 2001 and 2019

...and investment in biotech is growing⁴

179%

increase in amount invested via venture financing between 2001 and 2019

81%

biotech's share of the overall pipeline in 2019

^{4.} Venture Financing WW 2010-2019.



- Parexel has the expertise to guide you to make the most of this growing market
 - > ~100 former regulators and HTA assessors
 - ➤ 1,000+ consulting experts covering 110 countries
 - ➤ 100+ marketing applications and submissions (NDA, BLA, ANDA, MAA, JNDA, 501(k), etc.) per year
 - > 1,500+ clinical trial applications per year
 - ▶ 150+ market access strategy projects
 - ➤ 80+ meetings with global Regulatory Authorities (FDA, EMA, PMDA, NMPA, etc.) per year
 - ➤ Health Advances: 25 years, 2,500 projects, 140 employees, \$75 billion of client transactions

>>> We'll put our heart and soul into helping you solve your challenges – at every step

It's now more difficult and expensive than ever to get a molecule to market. A tragic fact that means some worthy drugs never make it to the patients who need them. That's why at Parexel Biotech, we focus on finding ways to simplify and speed up development in order to reduce costs.

While there's always more to do, here's how we're doing so far:

12%

faster start-up

than other CROs from final protocol available to first site initiated⁵

13%

shorter cycle

than industry average from final protocol available to database lock⁵

9%

faster turnaround times

than industry average from database lock to clinical study report approval⁵

Up to


20%

efficiency generated

in developing evidence platforms for compounds while identifying new value opportunities⁵

>>> Our operating model

We tailor our services for you, keeping our operational structure lean and our processes flexible, to reduce cost and improve efficiency.



>>> Like our hearts, our offices are in the right places



Mith Heart

>>> We're always available for a conversation

To learn more about Parexel's Biotech services, please contact:

James Anthony, Global Head, SVP, Parexel Biotech +1 513 206 0683 james.anthony@parexel.com

Annika Zetterstroem, Vice President, Business Development, Europe +46 704 836 847 annika.zetterstroem@parexel.com

Brian Yang, Corporate Vice President, Business Development, APAC +886 935 969 111 brian.yang@parexel.com

Parexel International Corporation

275 Grove Street, Suite 101C, Newton, MA 02466, United States +1 617 454 9300

Offices across Europe, Asia, and the Americas www.parexelbiotech.com

